91 results about "B-Cell Epitopes" patented technology

The invention is applicable to the technical field of biology, and provides an L7 / L12-PADRE sequence-multi-linked B cell epitope recombinant protein and a kit for detecting an anti-Brucella antibody. The recombinant protein is a multi-epitope tandem recombinant protein composed of Brucella ribosome L7 / L12 protein, a PADRE polypeptide sequence and multiple B cell epitopes, the amino acid sequence of the recombinant protein is as shown in SEQ ID No.1, and the recombinant protein is good in antigenicity. The anti-brucella antibody indirect ELISA (iELISA) detection method and kit established by taking the recombinant protein as the coating antigen have the characteristics of high sensitivity, strong specificity and good repeatability, are suitable for detecting the condition of generating the anti-brucella antibody by an organism, can clarify the immune background of brucella infection or brucellosis vaccine, and can be used for detecting the brucella infection or brucellosis vaccine. Basic data is provided for prevention and control of the Brucella disease of humans and animals, and meanwhile, the kit is conveniently applied to large-scale sample detection and epidemiological monitoring.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention provides a streptococcus suis vaccine recombinant fusion protein and a preparation method and application thereof, the recombinant fusion protein is a recombinant protein formed by series fusion of B cell epitopes of Sao, SLY and PepO proteins of streptococcus suis, and the amino acid sequence of the fusion protein is as shown in SEQ ID NO.1. After four-week-old weaned piglets are immunized by the fusion expression protein for 28 days, 80% and 60% of challenge protection rates can be provided for challenge of streptococcus suis type 2 and type 9 virulent strains respectively. The invention has great potential for clinical prevention and control of streptococcus suis infection.

The invention discloses an ILTV gD protein antigen epitope expression cassette, a recombinant virus and application, and relates to the field of gene and protein engineering. The ILTV gD protein antigen epitope expression cassette provided by the invention comprises T and B cell epitopes of gD protein derived from an infectious laryngotracheitis virus WG strain. The recombinant virus rH120-gD-T / B is obtained by replacing a 5ab gene of an infectious bronchitis virus H120 strain with a gene for coding an ILTV gD protein antigen epitope expression cassette. The recombinant virus has good genetic stability, can be used for developing a safe and effective IB-ILT bivalent live vector vaccine, and solves the problem of poor stability of the current recombinant IBV.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The invention belongs to the field of biological immunity, and discloses a linear B cell epitope of African swine fever virus NP419L protein and application. The epitope sequence shows good immunoreactivity through ASFV positive pig serum recognition verification. The African swine fever positive serum can be identified by using the B cell epitope identified by the invention to carry out ELISA (Enzyme-Linked Immunosorbent Assay) experiment, and the sensitivity of the African swine fever positive serum is superior to that of NP419L protein full length and other truncated fragments. The epitope identified by the invention has high conservative property in reference ASFV strains in a plurality of popular regions in China, and has wide universality and adaptability. The kit can be widely applied to etiological diagnosis, serological diagnosis, immunological detection and disease prevention and treatment of African swine fever viruses, and can be applied to preparation of African swine fever vaccines, pathogenesis research and the like.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides construction of a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of protective vaccines. The fusion recombinant protein ABT is composed of an immunological enhancement antigen and a multi-epitope tandem antigen, wherein the immunological enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence; the multi-epitope tandem antigen is formed by connecting a dominant B cell epitope part (named as B), a dominant Tc cell epitope part and a dominant Th cell epitope part (named as T) in series, wherein the dominant B cell epitope part (named as B) is derived from Brucella SurA, OMP31, BP26 and Trigger factor proteins. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immunologic adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate an organism to generate a protective antibody, and has long antibody maintenance time.

The invention relates to the technical field of biological medicine, and discloses a nanoparticle vaccine based on an HER2 target spot and application of the nanoparticle vaccine, and the nanoparticle vaccine based on the HER2 target spot comprises an HER-2 gene related antigen sequence HER2 and hepatitis B core virus-like particle nanoparticles HBc VLPs; the amino acid sequences of the gene are respectively shown as SEQ ID No. 1 and SEQ ID No. 2. According to the invention, hepatitis B core virus-like particles are modified by using B cell epitopes of HER2 targets, and the nanoparticle tumor vaccine suitable for intramuscular injection is prepared. The vaccine aims at reducing clinical safety risks and reducing immune tolerance and toxic and side effects caused by long-term use of monoclonal antibody drugs. Through an active immunization mode, an organism can continuously generate an anti-HER2 specific antibody, and clinical guidance is provided for research and development of therapeutic general tumor vaccines.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

The application discloses a duck Riemerella anatipestifer (RA) surface adhesion factor 3-glyceraldehyde-3-phosphate dehydrogenase protein (GAPDH) conservative B cell epitope peptide, a nucleic acid molecule, a recombinant carrier and application thereof. The application inserts the conservative B cell epitope TG12 into chicken white dysentery Salmonella Peg fimbria, introduces the inert carrier bacteria, and obtains the recombinant bacteria which can functionally express and present the RaGAPDH protein surface conservative B cell epitope peptide. The expression and presentation of the conservative B cell epitope can specifically recognize and combine duck and goose RA infection serum, and the naked-eye visible agglutination reaction particles are observed, and there is no cross agglutination reaction with other pathogen infection positive serum. The agglutination detection method has the advantages of specificity and convenience, and is expected to provide a new idea and method for detection and prevention and control of RA infection.

The present invention discloses a subunit vaccine against chicken infectious anemia virus, belonging to the technical field of animal disease vaccines. The present invention provides a subunit vaccine against chicken infectious anemia virus, and the active ingredient is a recombinant fusion protein of the B cell epitope of chicken infectious anemia virus VP1 protein and Salmonella typhimurium flagellin. The B cell epitope of chicken infectious anemia virus VP1 protein is obtained by connecting the B cell antigen epitopes contained in chicken infectious anemia virus VP1 protein through a linker peptide. The Salmonella typhimurium flagellin is obtained by deleting the hypervariable region of Salmonella typhimurium flagellin FliC. After the fusion expression protein of the present invention is administered to 1-day-old SPF chickens, it can induce the production of specific IgG antibodies, and after 28 days of immunization, the immunized chicken flock can resist the challenge of the virulent strain of chicken infectious anemia virus, and 70% of the challenged chicken flock is protected from disease. The present invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The invention relates to a preparation method of a babesiella bovis vaccine, belongs to the technical field of vaccines, and particularly relates to a combined vaccine based on silver nanoparticles (AgNPs) and theileria bovis antigen, the vaccine comprises 10-50nm AgNPs, the surface of the AgNPs is modified with carboxyl, amino or PEG, and the AgNPs are used for covalently coupling RAP-1 protein or immunogenic fragments thereof and MSA-2 protein or B cell epitope peptide thereof, the RAP-1 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 1), the MSA-2 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 2), and the preparation method comprises the following steps: carrier construction, recombinant expression, protein purification and AgNPs coupling to form a silver nanoparticle antigen compound, and the silver nanoparticle antigen compound is coated with chitosan to prolong the in-vivo half-life period.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

The invention relates to the technical field of microorganisms, and discloses construction and application of an enterotoxigenic escherichia coli K88 cilia display system. A K99 FanC sequence is subjected to B cell epitope prediction analysis, the FanC gene is divided into different antigen regions, the antigen regions are subjected to fusion expression with FaeG protein, the separated and purified fusion protein is used as an antigen to immunize mice, and the optimal fusion protein FaeG-EP3 is screened out, and the protein is shown as SEQ ID NO.9. The invention further discloses a preparation method of the FanC protein. While the Escherichia coli K99 ciliin epitope is fully exposed, the ciliin of the K88 native conformation is expressed, the original protein activity is ensured, and the protein expression is stable and efficient. And the method has important significance for solving the problem of complex types of porcine enterotoxigenic escherichia coli pili adhesin.

The present invention belongs to the technical field of vaccines and relates to an encephalomyocarditis multi-epitope recombinant protein, and the encephalomyocarditis multi-epitope recombinant protein comprises 8 B-cell epitopes and 1 signal peptide. The present invention also provides the application of the recombinant protein in the preparation of an encephalomyocarditis vaccine. With the goal of developing a safe and effective vaccine, the B-cell epitopes of VP1, VP2, and VP3 of the EMCV structural protein are screened, and a recombinant epitope protein with good hydrophilicity, strong antigenicity, and high surface accessibility is constructed. By immunizing BALB / c mice, it is found that it can induce the production of neutralizing antibodies and a Th1-dominated cellular immune response, and can protect the mice from EMCV attack. The results show that the MIgH-EMCV-II<supgt;2D2< / supgt; protein may be a potential candidate for developing a safe and effective multi-epitope vaccine to control EMCV infection.

The present invention discloses citrullinated SAA polypeptides and their application in the preparation of diagnostic products for rheumatoid arthritis. The amino acid sequence of the citrullinated SAA polypeptide is: DKYFHA-Cit-GNYDAAK-Cit-GPGGA. Through this polypeptide, the present invention has identified the citrullinated autoantigen B cell epitope of SAA and the corresponding autoantibody, namely anti-citrullinated SAA polypeptide antibody (anti-CAP). The expression level of anti-CAP in RA patients is significantly higher than that in other disease control groups and healthy groups, and it has a good positive rate in early RA, ESR / CRP normal RA, and anti-CCP antibody / RF negative RA, providing a new strategy for the diagnosis of RA.

The application discloses a porcine delta coronavirus S1-CTD protein linear B cell epitope peptide and application thereof, and belongs to the technical field of biological medicines. 585 EYLQVQAEQVIVDCP 599 The linear B cell epitope peptide can be recognized and combined by a monoclonal antibody of the porcine delta coronavirus S1-CTD protein, and provides technical support for research and development of porcine delta coronavirus related vaccines, medicines and diagnostic reagents.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention discloses a fusion protein for diagnosing mycoplasma bovis infection as well as a preparation method and application of the fusion protein. According to the fusion protein disclosed by the invention, dominant B cell epitope peptides of two strong immunogenic lipoproteins of mycoplasma bovis are connected, mycoplasma bovis infection can be effectively distinguished, and the fusion protein is further used for preparing a detection product for diagnosing mycoplasma bovis infection. A detection product prepared from the fusion protein disclosed by the invention has excellent sensitivity and specificity, and is of great significance for improving the economic benefit of the cattle breeding industry.

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The present invention discloses a B cell epitope on the surface of a glyceraldehyde-3-phosphate dehydrogenase protein, its nucleic acid molecule, and its application in detecting Mycoplasma hyopneumoniae infection. The B cell epitope of the present invention can be functionally expressed on the surface of an inert carrier S9 bacterium. Based on the LN7-antibody direct-mediated agglutination test detection method established by LN7 functionally expressed on the surface of the S9 bacterium, LN7 specifically recognizes only Mycoplasma hyopneumoniae infection serum antibodies and vaccine immune serum antibodies containing the GAPDH antigen, generating a specific binding reaction, while having no cross-reaction or non-specific binding reaction with other mycoplasma pathogens, porcine respiratory disease pathogen infection serum, and vaccine immune serum. This diagnostic method is expected to become an important technical means for the accurate diagnosis of Mycoplasma hyopneumoniae infection and the monitoring and evaluation of the immune effect of Mycoplasma hyopneumoniae vaccine.

The invention discloses a double-genotype goose astrovirus multi-epitope fusion protein and a preparation method and application thereof, and relates to the technical field of chemistry. Screening of GAstV positive serum; designing and synthesizing a B cell epitope of the GAstV cap protein; screening of dominant B cell epitopes of the single genotype GAstV cap protein; expression and purification of the fusion epitope all-CAP; establishing a fusion epitope ELISA antibody detection method; detecting a clinical sample; and making a detection conclusion according to a detection result. According to the double-genotype goose astrovirus multi-epitope fusion protein as well as the preparation method and the application thereof, prepared GAstV single-genotype positive goose serum is used for screening to obtain cap protein B cell epitope polypeptide with good reactivity, and the fusion epitope polypeptide all-CAP is obtained after tandem expression and purification; a universal indirect ELISA antibody detection technology which is strong in specificity, high in sensitivity and good in repeatability and can be used for common detection of GAstV-1 and GAstV-2 is established by taking the GAstV-1 and GAstV-2 as a coating antigen.

The invention relates to the field of molecular vaccinology, in particular to a vaccine aiming at severe malaria, and further relates to a multi-epitope fusion antigen vaccine derived from plasmodium falciparum STEVOR protein as well as preparation and application of the multi-epitope fusion antigen vaccine. The multi-epitope fusion antigen vaccine contains at least two amino acid fragments in a B cell epitope, a CD4 and T cell epitope and a CD8 and T cell epitope. The MEFA vaccine targeting STEVOR protein SC structural domain conservative immunodominant epitopes has broad spectrum, can realize 97.15% global HLA coverage rate through the conservative epitopes, can synchronously induce IgG antibody and CD4 + / CD8 + T cell response, is safe, has no toxicity / sensitization, and has good in-vivo and in-vitro stability (the mammalian half-life period gt; further, the strain is used for inducing wide immune response for resisting severe malaria, and is suitable for large-scale production of an escherichia coli or yeast expression system.

The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus, and a tandem epitope expression cassette is inserted between UL45 and UL46 of the recombinant turkey herpesvirus; the tandem epitope expression cassette is used for expressing a plurality of B cell epitopes and a plurality of T cell epitopes. According to the recombinant herpesvirus of turkeys, a tandem epitope is inserted into an HVT (herpesvirus of turkeys) vector, and experiments prove that the recombinant herpesvirus of turkeys can induce higher HI antibody and neutralizing antibody titer, obviously stimulate spleen T lymphocyte response of immunized chicken, and can generate an obvious challenge protection effect in 3 days; the challenge protection effect is obviously superior to that of a combined immunization scheme of H9N2 AIV multi-epitope recombinant baculovirus (BV-BNT) and InV provided by the applicant; meanwhile, the recombinant turkey herpesvirus is verified to be capable of performing intraembryonic vaccination and generating an obvious immune protection effect. Meanwhile, the invention further provides a preparation method and application of the recombinant turkey herpesvirus.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

The invention discloses a targeted B cell epitope peptide monoclonal antibody as well as a preparation method and application thereof, five B cell epitope peptide positive hybridoma cell strains: 2G6H3, 6F11B7, 6F11E4, 4H9D8 and 4H9B7 are successfully screened by utilizing a hybridoma cell technology, and the monoclonal antibody is purified. The five monoclonal antibodies can recognize B cell epitope peptide, rEm.P29 and P29 protein in natural antigen, and 6F11B7, 6F11E4 and 2G6H3 which are high in specificity and affinity are selected for evaluating the curative effect of an abdominal cavity infected animal model. The results show that the monoclonal antibody can significantly inhibit the growth of echinococcus multilocularis in mice, has a curative effect higher than that of a clinical drug albendazole, does not have side effects such as liver and kidney function impairment caused by chemotherapeutic drugs, and does not affect other organs. The invention has treatment potential and treatment safety, and provides a brand new treatment strategy for clinically treating the alveolar echinococcosis.

The invention discloses a glycopeptide compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The glycopeptide compound has a structure as shown in a formula (I) and comprises three components, namely a B cell epitope, a regulatory T cell epitope and rapamycin, and the three components are coupled through a KK protein joint. The invention further provides application of the glycopeptide compound in preparation of a medicine for treating anti-MAG neuropathy autoimmune diseases and a medicine composition. # imgabs0 #

The invention discloses a specific antigen fragment of salmonella typhimurium and application of the specific antigen fragment in detection of a salmonella typhimurium antibody. The amino acid sequence of the salmonella typhimurium specific antigen fragment is as shown in SEQ ID NO. 1. The invention discloses a method for detecting the indirect ELISA antibody of the salmonella typhimurium by taking the specific antigen fragment of the salmonella typhimurium as the coating antigen of the indirect ELISA for the first time, the specific antigen fragment of the salmonella typhimurium contains dominant B cell epitopes of the FliC protein of the salmonella typhimurium, and the specific antigen fragment of the salmonella typhimurium contains the dominant B cell epitopes of the FliC protein of the salmonella typhimurium. The salmonella typhimurium FliC protein antibody generated by induction can be specifically recognized, and the obvious synergistic effect is achieved in the aspect of improving the specific binding of the antigen and the antibody. The kit can be used for detecting the salmonella typhimurium antibody, and provides powerful technical support for epidemiological investigation of salmonella typhimurium and prevention and control of salmonella.